Related Experiment Video

Updated: Aug 2, 2026

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones

A C Teisman1, D J van Veldhuisen, F Boomsma

  • 1Department of Clinical Pharmacology, University of Groningen, Groningen, The Netherlands. cliphar@med.rug.nl

International Journal of Cardiology
|April 5, 2000
PubMed
Abstract

Insights

Chronic beta-blocker therapy in heart failure patients significantly lowers plasma renin levels, suggesting sustained inhibition of harmful neurohormones. This supports beta-blockers as a crucial treatment for managing chronic heart failure progression.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are increasingly used for chronic heart failure, with trials showing reduced mortality.
  • Beneficial effects may stem from inhibiting detrimental neurohormone activation in heart failure progression.
  • This study investigates if neurohormone inhibition is maintained with chronic beta-blocker use.

Purpose of the Study:

  • To evaluate the effect of chronic beta-blocker treatment on neurohormone activation in patients with chronic heart failure.
  • To compare neurohormonal profiles between patients with and without beta-blockers, alongside ACE-inhibitors.

Main Methods:

  • Retrospective analysis of neurohormonal profiles in moderate to severe chronic heart failure patients.
  • Three treatment groups: no beta-blockers/ACE-inhibitors, ACE-inhibitors only, and both beta-blockers and ACE-inhibitors.
  • Average beta-blocker treatment duration of 3.8 years, with plasma samples collected under controlled conditions.

Main Results:

  • Patients on chronic beta-blockers showed significantly lower plasma renin levels compared to those on ACE-inhibitors alone.
  • Plasma aldosterone and endothelin-I levels trended lower with beta-blocker use, but did not reach statistical significance.
  • Groups were well-matched for clinical characteristics despite uneven sample sizes.

Conclusions:

  • Chronic adjunctive beta-blocker treatment significantly reduces plasma renin levels compared to ACE-inhibitor monotherapy.
  • This sustained reduction in plasma renin may prevent the escape of neurohormones, contributing to heart failure management.
  • Beta-blockers play a key role in mitigating neurohormonal activation in chronic heart failure.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...